Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome

Trial Profile

An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Atypical Haemolytic Uraemic Syndrome
  • Focus Therapeutic Use
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 12 Dec 2021 Results of patient-level data from four eculizumab clinical trials (C08-002A/B (NCT00844545/NCT00844844), C10-003 (NCT01193348), and C10-004 (NCT01194973) were available for pooling and comparison with data from two ravulizumab trials (ALXN-aHUS-311 (NCT02949128) and ALXN-aHUS-312 (NCT03131219) assessing the effectiveness of ravulizumab and eculizumab for the treatment of aHUS, accounting for observed differences between clinical studies, published in the Clinical Nephrology.
    • 05 May 2015 Results published in the Alexion Pharmaceuticals Media Release.
    • 05 May 2015 According to Alexion Pharmaceuticals media release, the data from post-hoc sub-analysis was presented at American Transplant Congress (ATC) 2015.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top